Breast Cancer Clinical Trials & Research at Providence Medical Group

In the U.S., breast cancer is the second most common cancer in women after skin cancer. It can occur in both men and women. The most common type of breast cancer is ductal carcinoma, which begins in the cells of the ducts. Breast cancer can also begin in the cells of the lobules and in other tissues in the breast. Invasive breast cancer is breast cancer that has spread from where it began in the ducts or lobules to surrounding tissue.

Providence Medical Group is currently enrolling patients for the following breast cancer clinical trials:


A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Nab-Paclitaxel or Paclitaxel versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients with Metastatic Triple-Negative Breast Cancer

Treatment agent: Magrolimab + Nap-Paclitaxel or Paclitaxel vs. Nab-Paxlitaxel or Paclitaxel
PI: Jarrod Holmes, MD
Study Coordinator: Teresa Lund
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04958785?term=NCT04958785&draw=2&rank=1
Sponsor: Gilead Sciences


Study to Assess the Effect of PF_06946860 on Appetite Following Subcutaneous Administration to Patients with Anorexia and Advanced Cancer

Treatment agent: PF-06946860
PI: Sara Keck, MD
Study Coordinator: Melissa Phillips // Melissa.Phillips2@stjoe.org// (707) 521-3833 ext. 1313
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04803305?term=PF-06946860&draw=2&rank=2
Sponsor: Pfizer


A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology

Treatment agent: Berzosertib, Topotecan Hydrochloride
PI: Ian Anderson, MD
Study Coordinator: Camille Shaffer
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04639219?term=04639219&draw=2&rank=1
Sponsor: AstraZeneca


Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Treatment agent: AZD9833 + Palbociclib/Abemaciclib vs Letrozole/Anastrazole + Palbociclib/Abemaciclib
PI: Manasa Vulchi, MD
Study Coordinator: Camille Shaffer // Camille.Shaffer@stjoe.org // (707) 521-3809 ext. 1182
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04964934?term=NCT04964934&draw=2&rank=1
Sponsor: AstraZeneca


Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer (ARTEST)

Treatment agent: Enobosarm vs Esemestane, esemestane + everolimus, or SERM
PI: Jarrod Holmes, MD
Study Coordinator: Teresa Lund // Teresa.Lund@stjoe.org // (707) 521-3803 ext. 1103
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04869943?term=NCT04869943&draw=2&rank=1
Sponsor: Veru Inc.


ASCENT-04 GS 548-6173:

Randomized Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Vs Treatment of Physician’s Choice and Pembro in 1L Locally Advanced Inoperable orMetastatic TNBC PDL1 +
Study Coordinator: Melissa Phillips // Melissa.Phillips2@stjoe.org// (707) 521-3833 ext. 1313
Key I/E: PDL1 pos


GS-US-586-6144:

Phase 2 Study of Magrolimab + sacituzumab govitecan in unresectable/metastatic TNBC Previously Untreated Met TNBC
Study Coordinator: Teresa Lund // Teresa.Lund@stjoe.org // (707) 521-3803 ext. 1103
Key I/E: PDLI neg, 1 prior line Rx metastatic , prior taxane met or neoadj, if PDL1+ then have recived
Rx: antiCD47 Ab blocks don’t eat me signal on tumors, can cause anemia


Abbvie 037:

Phase 1 Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 (CD40 Ab)
Study Coordinator: Tracy x1136
Key I/E: Arms 1-3, PD after at least 1 prior Rx including taxane, no prior platinum or immunoRx; Arm 4 1st line PD-L1
Rx: dose-escalation -> expansion, IV


PROFOUND:

Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors
Study Coordinator: Tracy x1136
Key I/E: no SOC options remaining, CrCl >=60, CNS mets if stable 4 wks prior to study
Rx: PRO1184 is an ADC targeting Fra (folate receptor alpha)

Our Providers

Our Locations